PDF herunterladen
CC BY-NC-ND 4.0 · Asian J Neurosurg 2020; 15(03): 683-685
DOI: 10.4103/ajns.AJNS_83_20
Case Report

Cisplatin-related cerebral infarction in carcinoma of the external auditory canal

Makoto Kadowaki
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu
,
Yoshinobu Kamio
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu
,
Hisaya Hiramatsu
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu
,
Hiroki Namba
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Background: Despite the known association between cisplatin and vascular toxicity, the mechanism of cisplatin-associated cerebral infarction, a relatively rare complication, remains unclear. We describe an investigation of potential biomarkers that could facilitate the early detection of this complication in a relevant case. Case Description: A 59-year-old male diagnosed with stage III carcinoma of the external auditory canal underwent cisplatin chemotherapy. Seven days after the last dose, he presented with a disturbance of consciousness due to basilar artery occlusion, which was associated with chemotherapy administration. The patient recovered consciousness after thrombectomy. Interestingly, an increase in serum von Willebrand factor (vWf) activity was observed. The vWf activity level gradually normalized 5 months after cisplatin administration. Conclusions: Endothelial injuries could be responsible for cisplatin-associated cerebral infarction. Moreover, a cisplatin-induced cerebral infarction increase in serum vWf activity, which indicates endothelial injury, suggests that this molecule might be a useful biomarker for predicting cisplatin-associated cerebral infarction.

Key-words:

Cerebral infarction - cisplatin - vascular toxicity - von Willebrand factor

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 08. März 2020

Angenommen: 21. Mai 2020

Artikel online veröffentlicht:
16. August 2022

© 2020. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 2011;29:3466-73.
  • 2 Ohashi S, Yazumi S, Nishio A, Fukui T, Asada M, Chiba T. Acute cerebral infarction during combination chemotherapy with s-1 and cisplatin for a young patient with a mucin-producing adenocarcinoma of the stomach. Intern Med 2006;45:1049-53.
  • 3 Sato C, Okuda K, Tamiya H, Yamamoto K, Hoshina K, Narumoto O, et al. Acute arterial thrombosis during postoperative adjuvant cisplatin-based chemotherapy for completely resected lung adenocarcinoma. Intern Med 2018;57:557-61.
  • 4 Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res 2011;31:4501-5.
  • 5 Lange J, Audebert HJ, Endres M, Rocco A. Cisplatin-related cerebral infarction in testicular germ cell cancer: Short report of three cases and P in testicular germ cell cancer: Short report of three cases and pathomechanism. Clin Neurol Neurosurg 2017;152:76-7.
  • 6 Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clin Neurol Neurosurg 2006;108:150-6.
  • 7 Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103:994-9.
  • 8 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
  • 9 Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25:47-58.
  • 10 Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010;23:247-53.
  • 11 Horvath B, Hegedus D, Szapary L, Marton Z, Alexy T, Koltai K, et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol 2004;9:31-4.
  • 12 Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547-51.
  • 13 Menih M, Križmarić M, Hojs Fabjan T. Clinical role of von Willebrand factor in acute ischemic stroke. Wien Klin Wochenschr 2017;129:491-6.
  • 14 Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009;113:3600-3.